BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank check company formed to pursue a business combination in the oncology and life sciences sector. The company filed an 8-K current report with the SEC on June 22, 2026, signaling a material corporate development to investors. BBOT operates within the healthcare and biopharmaceutical SPAC cohort, a segment that has attracted significant sponsor activity as acquirers seek clinical-stage oncology platforms. The filing, assigned accession number 0001193125-26-277513, is part of the public record maintained by the Commission. For the complete picture on BBOT — including sponsor identity, IPO details, deal timeline, and full filing history — sign up for access at SpacDesk.